Compare WFCF & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WFCF | LUNG |
|---|---|---|
| Founded | 1996 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Industrial Specialties |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.3M | 72.2M |
| IPO Year | 2006 | 2020 |
| Metric | WFCF | LUNG |
|---|---|---|
| Price | $12.16 | $1.35 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | 1.2K | ★ 680.2K |
| Earning Date | 05-07-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.64 |
| EPS | ★ 0.30 | N/A |
| Revenue | $20,774,416.00 | ★ $90,497,000.00 |
| Revenue This Year | N/A | $6.20 |
| Revenue Next Year | N/A | $21.61 |
| P/E Ratio | $39.19 | ★ N/A |
| Revenue Growth | ★ 16.69 | 8.01 |
| 52 Week Low | $9.69 | $1.31 |
| 52 Week High | $13.70 | $7.97 |
| Indicator | WFCF | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 58.25 | 37.62 |
| Support Level | $11.90 | N/A |
| Resistance Level | $12.68 | $2.01 |
| Average True Range (ATR) | 0.16 | 0.17 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 87.21 | 5.29 |
Where Food Comes From Inc is a third-party food verification company conducting both on-site and desk audits to verify that claims being made about livestock, food, other high-value specialty crops and agricultural and aquaculture products are accurate. The company supports farmers, ranchers, vineyards, wineries, processors, retailers, distributors, trade associations, and restaurants with a wide variety of value-added services provided through its family of verifiers, including International Certification Services, Validus Verification Services, and others. It also provides a wide range of professional consulting services. It generates the majority of its revenue from Verification and certification services.
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.